P Buggisch
Overview
Explore the profile of P Buggisch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tergast T, Protzer U, Zeuzem S, Heitmann L, Sarrazin C, Lehmann M, et al.
Z Gastroenterol
. 2023 Feb;
61(2):198-201.
PMID: 36736343
No abstract available.
2.
Cacoub P, Buggisch P, Carrion J, Cooke G, Zignego A, Beckerman R, et al.
J Viral Hepat
. 2018 Feb;
25(7):811-817.
PMID: 29476572
Hepatitis C virus (HCV) infection is a systemic disease associated with both hepatic and extrahepatic manifestations. The burden associated with the hepatic manifestation of HCV infection has been well documented...
3.
Welzel T, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, et al.
J Viral Hepat
. 2017 Mar;
24(10):840-849.
PMID: 28342229
Real-world studies are relevant to complement clinical trials on novel antiviral therapies against chronic hepatitis C; however, clinical practice data are currently limited. This study investigated effectiveness and safety of...
4.
Huppe D, Buggisch P, Christensen S, Heiken H, Mauss S, Naumann U, et al.
Z Gastroenterol
. 2016 Aug;
54(8):740-7.
PMID: 27529525
In 2014, the first interferon-free treatment options for chronic Hepatitis C (CHC) became available in Europe introducing a new era of highly effective and well tolerated oral treatment options for...
5.
Fulop B, Mihm U, Rohde P, Buggisch P, Schlosser B, Biermer M, et al.
J Viral Hepat
. 2016 Jun;
23(11):866-872.
PMID: 27346846
The mode of action of ribavirin is not completely understood. Ribavirin monotherapy has a measurable antiviral effect, which shows great variability. It might lead to an earlier steady state of...
6.
Zeuzem S, Flisiak R, Vierling J, Mazur W, Mazzella G, Thongsawat S, et al.
Aliment Pharmacol Ther
. 2015 Aug;
42(7):829-44.
PMID: 26238707
Background: Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance. Aim: To evaluate efficacy and safety of ALV plus...
7.
Mauss S, Boker K, Buggisch P, Christensen S, Hofmann W, Schott E, et al.
Z Gastroenterol
. 2015 Jul;
53(7):644-54.
PMID: 26167694
Background And Aims: The efficacy and safety of peginterferon alfa-2a (PEG-IFN) plus ribavirin (RBV) and either boceprevir (BOC) or telaprevir (TVR), and physician adherence to treatment algorithms were evaluated in...
8.
Friedrich-Rust M, Lupsor M, de Knegt R, Dries V, Buggisch P, Gebel M, et al.
Ultraschall Med
. 2015 May;
36(3):239-47.
PMID: 25970201
Purpose: The aim of the present prospective European multicenter study was to demonstrate the non-inferiority of point shear wave elastography (pSWE) compared to transient elastography (TE) for the assessment of...
9.
Sarrazin C, Berg T, Buggisch P, Dollinger M, Hinrichsen H, Hofer H, et al.
Z Gastroenterol
. 2015 Apr;
53(4):320-34.
PMID: 25867048
No abstract available.
10.
Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis
Wiegand J, Maasoumy B, Buggisch P, Buslau A, Schiefke I, Berg T, et al.
Aliment Pharmacol Ther
. 2014 May;
39(11):1342-4.
PMID: 24803258
No abstract available.